These include cytokeratin-18 (CK-18), fibroblast grown factor 21 (FGF21)18, 19 and NAFLD fibrosis score, in combination with non-invasive methods developed in the hepatitis C setting e.g. the Sydney Index. Here, KRT18 is linked to metabolic dysfunction-associated steatotic liver disease.